Bajaj Healthcare launches Ivejaj for treatment of Covid-19

Bajaj Healthcare has announced the launch of Ivejaj (Ivermectin) an Anti Parasitic Drug now widely used in control & treatment for Covid-19 patients. The company has received approval from India's drug regulator, to manufacture and market Ivejaj the oral Ivermectin approved medication in India for the treatment of COVID-19 from 6 May 2021.

IVEJAJ Tablets comprising Ivermectin. Ivermectin is an Anti-Parasitic Drugs, which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of Covid-19 Patients. It works by paralyzing and killing parasites.

The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj. The drug will be available as a prescription-based medication, with recommended doses.

 

The drug controller of India's has granted permissions to supply the Ivejaj (Ivermectin) in the domestic as well as in overseas market.

Powered by Capital Market - Live News